NIH R01 · 2025
Optimizing lipid RVn monophosphate prodrugs to maximize RVn-triphosphate delivery
PROJECT SUMMARY/ABSTRACT Emerging RNA viruses, especially respiratory viruses, are among the leading threats to global health. With few treatments currently available, there is an urgent and ongoing need for the development of safe, effective oral antivirals. The objective of this application is to optimize an innovative lipid prodrug delivery strategy for remdesivir nucleoside monophosphate (RVn-MP), and additional broad-spectrum nucleoside antivirals, to achieve 1) excellent oral bioavailability, 2) efficient intracellular activation across tissue types, and 3) bypass of liver metabolism to enhance tissue delivery. The central hypothesis is that specific modifications to the lipid prodrug…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.